Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29178586 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL4681123 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL34468363 | 0.86 | NR1H2 (0.51) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL4677693 | 0.86 | NR1H2 (0.51) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL4677686 | 0.86 | NR1H2 (0.51) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL5881516 | 0.86 | NR1H2 (0.51) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL30155479 | 0.84 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL2378746 | 0.84 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL25470765 | 0.81 | CHRM2 (0.56) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL24372084 | 0.81 | CHRM2 (0.56) | CHRM2CHRM1CHRM3NR1H2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | CHRM2 833/4885CHRM1 212/4885CHRM3 1916/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | CHRM2 833/4885CHRM1 212/4885CHRM3 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.